Content Type: Article

  • International News: Employment

    International News: Employment

    INTERNATIONAL NEWS / REPORT

    International News: Employment

    September 2019

    Read time: 2 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • Life Sciences Company Settles Regulation FD Charges with SEC

    Life Sciences Company Settles Regulation FD Charges with SEC

    ARTICLE / CLIENT ALERT

    Life Sciences Company Settles Regulation FD Charges with SEC

    September 4, 2019

    Read time: 6 min

    Key takeaways
    Overview

    On August 20, 2019, the US Securities and Exchange Commission (SEC) charged TherapeuticsMD Inc., a Boca Raton, Florida, headquartered life sciences company, with violations of Regulation FD for sharing material, non-public information with sell-side analysts about the company’s interactions with the US Food and Drug Administration (FDA). While neither admitting nor denying the SEC charges, the company settled by paying a fine of $200,000. The settlement demonstrates the importance of companies having an established Regulation FD policy and ensuring that employees are adequately trained in complying with such a policy.

    In depth

    Regulation FD prohibits public companies, or persons acting on their behalf, from selectively disclosing material, non-public information to certain persons outside the company. In the TherapeuticsMD matter, the SEC charged the company with two separate violations of Regulation FD for selectively disclosing details about a meeting between the company and the FDA regarding a drug candidate for which the company had previously filed a New Drug Application (NDA).

    On June 14, 2017, the company met with the FDA to discuss safety concerns related to the drug candidate subject to the NDA; the company had previously publicly disclosed the FDA meeting. On June 15, the company sent emails to sell-side analysts describing the meeting as “very positive and productive,” had follow up calls with certain analysts to discuss the meeting, and, in a follow-up email to one analyst, indicated that the company was “pleasantly surprised at how accommodating” the FDA officials were. On June 16, the company’s stock price increased 19.4% on heavy volume. Market watch officials from the New York Stock Exchange (NYSE) contacted the company, but the executives with whom they spoke did not know of the emails sent to analysts the prior day, believed that market events could have caused the volatility in the company’s stock price, and told the NYSE officials that they were not aware of any material information affecting the stock.

    On July 17, 2017, the company issued a press release and filed a Form 8-K prior to market open following receipt from the FDA of the June 14 meeting minutes, indicating that the company had been able to present “new information” to the FDA at the meeting to address safety concerns raised by the FDA and to “positively affect” the status of the NDA, but that the company did not have a clear path forward regarding the NDA. The company’s stock price fell approximately 16% in pre-market and early trading, prompting questions from sell-side analysts as to what the press release meant. At a pre-scheduled 7:30 am conference call with sell-side analysts, the company discussed the new information provided to the FDA during the meeting, which consisted of three previously published medical studies and one long-term National Institutes of Health study, the results of which had not yet been published. The three published studies were emailed to analysts along with a statement by the company’s chief medical officer indicating that, based on the findings in the studies, the drug candidate “posed no safety risk.” After the call, the sell-side analysts published notes conveying information about the studies provided to the FDA and the finding of no safety risks related to the drug candidate, leading to a rise in the company’s stock price, which finished down only 6.6% by market close.

    The SEC found that the disclosures to the sell-side analysts on June 14 and July 17 were each instances of providing material, non-public information, and, because the company failed to simultaneously or promptly publicly disclose that information, that such disclosures constituted violations of Regulation FD. Furthermore, the SEC noted that the company did not have a policy in place with respect to Regulation FD disclosure. The company subsequently implemented such a policy, however, and this remedial action was considered in connection with the settlement.

    The settlement offers some important lessons for companies.

    • While a company might conclude that neither a statement as to “the positive and productive” nature of a meeting with a regulatory agency nor granular information on specific studies or information provided to a regulatory agency warrants public disclosure, providing different information to the public and to sell-side analysts can potentially constitute a Reg FD violation.
    • It is important for companies not to share any material, non-public information, or information that may be construed as such, with sell-side analysts and others who do not have a “need to know.” Shared information is evaluated with the benefit of hindsight, and a seemingly innocuous statement might lead to significant movements in stock price, triggering the scrutiny of the SEC, the stock exchanges or other regulators.
    • While a company should always be vigilant of its communications, at critical inflection points such as FDA meetings, trial commencement and the public release of results—each of which spark interest in analysts and investors alike—there is an increased likelihood of Regulation FD violations occurring due to the tendency of such events to affect stock prices.
    • To the extent that a company does not already have a Regulation FD or communications policy in place, it should consider developing such a policy, including relevant disclosure controls, and provide training on the policy to all relevant employees.
    • Companies should expect to be contacted by the stock exchanges, FINRA or the SEC if there is unusual trading activity in the company’s stock, and should be prepared to respond to the question of whether the company is aware of any material information affecting the stock. Because all team members will not necessarily have access to the same information, a coordinated response is important, and appropriate internal inquiries should be made before answering.
    • Although not subject to Regulation FD, foreign private issuers should nevertheless comply with Regulation FD as a corporate governance matter and to avoid liability for potential selective disclosures under the anti-fraud provisions of the securities laws.
    Authors

    Thomas P. Conaghan

    Partner

    Washington, DC, New York – One Vanderbilt Avenue

    Eric Orsic

    Partner

    Chicago

    Heidi J. Steele

    Partner

    Chicago

    More insights

  • M&A Review – MuMAC Special 2019

    M&A Review – MuMAC Special 2019

    ARTICLE

    M&A Review – MuMAC Special 2019

    September 2, 2019

    Read time: 2 min

    Key takeaways
    Overview

    McDermott is pleased to be featured in the ninth issue of M&A Review highlighting our upcoming conference MuMAC 2019: 10 Years of Growth – What Comes Next.  The feature contains a number of articles by our McDermott lawyers and other industry experts, delving into various aspects of cross border M&A.

    In depth
    Authors
    More insights

  • FDIC and OCC Approve Volcker 2.0 — Summary of Amendments to Fund Activity Provisions

    FDIC and OCC Approve Volcker 2.0 — Summary of Amendments to Fund Activity Provisions

    ARTICLE / CLIENT ALERT

    FDIC and OCC Approve Volcker 2.0 — Summary of Amendments to Fund Activity Provisions

    August 23, 2019

    Read time: 14 min

    Key takeaways
    Overview

    On Aug. 20, 2019, the Federal Deposit Insurance Corporation (“FDIC”) and the Office of the Comptroller of the Currency (“OCC”) approved a final rule (“Final Rule”) to amend the regulations adopted in 2013 (“2013 Rule”) implementing Section 13 of the Bank Holding Company Act, commonly referred to as the “Volcker Rule.”[1] While the Final Rule is largely similar to the Notice of Proposed Rulemaking issued by the agencies on May 30, 2019 (“Proposed Rule”), it does contain important modifications from the Proposed Rule. The other three agencies charged with implementing the Volcker Rule — the Commodity Futures Trading Commission (“CFTC”), Federal Reserve Board (“Board”) and the Securities and Exchange Commission (“SEC” together with the FDIC, OCC, CFTC and Board, “Agencies”) — are expected to approve the Final Rule in the coming days. A copy of the Final Rule is available here.[2]

    This Alert[3] analyzes the Final Rule as it would affect a banking entity’s investments in, or sponsorship of, private investment funds.[4] While nearly all of the Final Rule concerns the Volcker Rule’s restrictions on a banking entity’s proprietary trading and its compliance program requirements, it does affect “covered fund”[5] activities in several ways. As discussed in further detail below, each of these changes provides more flexibility with regard to the relevant activity. Perhaps more importantly, however, the Agencies have indicated that they intend to make further (and likely more impactful) changes to the covered fund provisions. To that end, the Agencies intend to issue a separate proposed rulemaking to that effect shortly.[6]

    Greater Capacity for Underwriting and Market Making of Third-Party Covered Funds

    The 2013 Rule allows banking entities to hold ownership interests in covered funds when the entity is engaged in underwriting and market making-related activities so long as certain requirements are met, including that any fund ownership interests held, directly or indirectly, by the banking entity and its affiliates pursuant to this exemption (i) are deducted from tier 1 capital (for all regulatory purposes); and (ii) do not exceed 3% of the resulting tier 1 capital (“aggregate limit”) (together with any other investments that are subject to the aggregate limit). The Final Rule eliminates the tier 1 capital deduction and aggregate limit requirement for the value of ownership interests in third-party covered funds acquired or retained in accordance with the underwriting or market-making exemption, giving banking entities greater capacity to engage in underwriting and market making of such funds. The Final Rule does not eliminate the tier 1 capital deduction and aggregate limit for covered funds advised by the banking entity or covered funds that the banking entity organizes and offers. In implementing this change, the Agencies believed that the change would better align the compliance requirements for underwriting and market making involving covered funds with the risks those activities entail.

    More Flexibility for Investing in a Covered Fund as a Hedge

    Hedging Risk Associated with a Specific Customer Request Permitted

    The 2013 Rule permits a banking entity to hold an ownership interest in a covered fund in order to “demonstrably reduce” or “significantly mitigate” the “specific, identifiable” risks to the banking entity from a compensation arrangement with an employee (or an employee of an affiliate) that directly provides investment advisory or other services to that fund. The Final Rule extends this exemption to allow a banking entity to acquire or retain an ownership interest in a covered fund as a hedge when acting as an intermediary on behalf of a customer that is not itself a banking entity to facilitate the exposure by the customer to the profits and losses of the covered fund. The banking entity’s acquisition or retention of the ownership interest as a hedge must be designed to reduce or otherwise significantly mitigate one or more specific, identifiable risks arising out of a transaction conducted solely to accommodate a specific customer request with respect to the covered fund (i.e., the transaction must be customer-driven and the banking entity cannot rely on this exemption to facilitate the banking entity’s own exposure to a covered fund).

    To avail itself of this customer-driven transaction exemption, like the employee compensation arrangement exemption, a banking entity must have internal written policies and controls to ensure compliance with the requirements associated with such hedging activity. Further, to the extent such activity significantly increases the likelihood that the banking entity would incur a substantial financial loss or would pose a threat to the financial stability of the United States, it would not be permissible.

    A Reasonably Designed Hedge Permitted, Even If Ultimately Unsuccessful

    The Final Rule also eliminates the requirement that a permissible hedging transaction “demonstrably reduces or otherwise significantly mitigates” the relevant risks for both the employee compensation arrangement and the customer-driven transaction exemption. Instead the activity will be permissible so long as it was designed to reduce or otherwise significantly mitigate the specific, identifiable risk. The Agencies noted that it appears that the requirement to show that hedging activity demonstrably reduces a specific, identifiable risk that develops over time can be complex and could potentially reduce bona fide risk-mitigating hedging activity. For example, a banking entity may determine not to enter into what would otherwise be a reasonably designed hedge of foreseeable risks out of concern that the banking entity may not be able to effectively comply with the requirement that such a hedge demonstrably reduces such risks due to the possibility that unforeseen risks occur. This change is consistent with the statutory language of the Volcker Rule, which does not contain a similar requirement.

    Financing from U.S. Affiliates Permitted for Certain Non-U.S. Fund Activity by Non-U.S. Banks

    Under the Volcker Rule, certain eligible non-U.S. banking entities[7] are permitted to sponsor or hold ownership interests in certain eligible covered funds,[8] so long as such activity occurs “solely outside the United States” (commonly referred to as “SOTUS” exemption). Under the 2013 Rule, for such activity to occur “solely outside the United States” certain criteria need to be met, including that no financing is provided, directly or indirectly, by a branch or affiliate organized or located in the United States (“financing prong”).[9] The Final Rule removes this financing prohibition from the list of “solely outside the United States” requirements. Removing the financing prohibition is intended to streamline the requirements of this exemption with the intention of improving the implementation of the statutory exemption. The Agencies indicated that removing this prohibition addresses concerns that the fungibility of financing has made the prohibition difficult to apply in practice.

    Agency Guidance Giving Non-U.S. Banks Greater Flexibility for SOTUS Activity Codified

    Prior Agency Guidance on SOTUS Marketing Restriction Codified

    For eligible non-U.S. banking entities to hold ownership interests in covered funds under the SOTUS exemption, no ownership interest in such fund can be offered for sale or sold to a resident of the United States. The Final Rule codifies existing staff guidance on this issue,[10] by explicitly providing that the foregoing restriction is satisfied even if the relevant fund offers or sells its ownership interests to U.S. persons, so long as the banking entity or any of its affiliates do not participate in such marketing or sales. Absent this prior Agency guidance, the 2013 Rule would have drastically reduced the scope of funds in which a non-U.S. banking entity could invest pursuant to the SOTUS exemption.

    The Final Rule also explicitly clarifies that if the banking entity or an affiliate sponsors or serves, directly or indirectly, as the investment manager, investment adviser, commodity pool operator or commodity trading advisor to a covered fund, then the banking entity or affiliate will be deemed for purposes of this restriction to participate in any offer or sale of the fund’s ownership interests. This restriction constrains the non-U.S. banking entity in connection with its own activities with respect to covered funds rather than the activities of unaffiliated third parties.

    Prior Agency Guidance on SOTUS Sponsorship Restrictions Codified

    Under the SOTUS exemption, eligible non-U.S. banking entities[11] may sponsor an eligible covered fund,[12] without regard to the Volcker Rule’s sponsorship requirements, provided certain criteria are satisfied. For purposes of this exemption, the Agencies previously indicated that the U.S. personnel of a non-U.S. banking entity may provide investment advice and recommendations to the manager or general partner of a covered fund so long as that investment advisory activity in the United States does not result in the U.S. personnel participating in the control of the covered fund or offering or selling an ownership interest to a resident of the United States. Under the Final Rule, the Agencies have removed language from the SOTUS exemption that could be read as prohibiting any involvement by individuals in the United States. In doing so, they further confirmed that the SOTUS exemption does not preclude a non-U.S. banking entity from engaging a non-affiliated U.S. investment adviser, so long as the actions and decisions of the banking entity as principal occur outside the United States.

    Deadline for Annual CEO Certification for Prime Brokerage Exception to “Super 23A” Codified

    The Volcker Rule provides that a banking entity may not enter into any transaction with any covered fund for which such entity serves as sponsor, investment manager, investment adviser or commodity trading advisor, or which it otherwise organizes and offers, if the transaction would constitute a “covered transaction” as defined in Section 23A of the Federal Reserve Act (“Section 23A”) (such prohibition commonly referred to as, “Super 23A”[13]). Super 23A does not apply to prime brokerage transactions with a covered fund in which a covered fund sponsored, managed or advised by the banking entity (or an affiliate thereof) invests.[14] This exemption is available so long as certain enumerated conditions are satisfied, including that the chief executive officer (or equivalent officer) of the banking entity certifies annually that the banking entity does not, directly or indirectly, guarantee, assume or otherwise insure the obligations or performance of the covered fund or any covered fund in which such fund invests. The 2013 Rule provided no timeframe when such a certification was to be provided. Agency staff issued guidance as to when a banking entity was required to provide the certification during the conformance period.[15] The Final Rule codified such Agency staff guidance and requires that the certification be provided no later than March 31 of the relevant year. The CEO (or equivalent officer) has a duty to update the certification if the information in the certification materially changes at any time during the year when he or she becomes aware of the material change.

    Special Documentation Obligations Eliminated for Banking Entities Without Significant Trading Activities

    The Final Rule significantly amends the compliance program requirements of the 2013 Rule, providing banking entities with certain relief (with such relief increasing inversely to the size of the banking entities’ trading activities). Among the more general changes, the Final Rule significantly reduces the documentation burden resulting from covered fund activities for most banking entities. Under the 2013 Rule, a banking entity with greater than $10 billion in consolidated assets must maintain certain detailed documentation regarding its covered fund activities. Under the Final Rule this requirement now only applies to banking entities with “significant trading assets and liabilities,” which under the Final Rule defines those banking entities with $20 billion or more of trading assets and liabilities.[16]

    Authored by Joseph P. Vitale and Jessica Romano.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] 12 U.S.C. § 1851. The Volcker Rule generally restricts the proprietary trading and private investment fund activities of U.S. banks and their affiliates, as well as non-U.S. banks with a branch or agency office in the U.S. and their affiliates (collectively, “banking entities”).

    [2] The effective date for the Final Rule is Jan. 1, 2020. However, banking entities have until Jan. 1, 2021 to comply with the Final Rule. The 2013 Rule will remain in effect until that compliance date. Alternatively, a banking entity may voluntarily comply, in whole or in part, with the Final Rule prior to the compliance date, subject to the Agencies’ completion of necessary technological changes.

    [3] Upcoming Alerts will summarize the Final Rule’s effect on proprietary trading and compliance programs.

    [4] Under the 2013 Rule, a banking entity is generally barred from acquiring or retaining, as principal, an ownership interest in a covered fund, subject to certain exceptions. Further, a banking entity may not sponsor any covered fund, unless it abides by a series of requirements (or the sponsorship falls within an exception for non-U.S. activity).

    [5] Under the 2013 Rule, “covered funds” generally include “3(c)(1)” and “3(c)(7)” funds or their commodity pool or non-U.S. fund equivalents, subject to certain exceptions. The “covered fund” definition has not been changed as a result of the Final Rule.

    [6] While the Proposed Rule sought comments on numerous aspects of the covered fund provisions (including the defined term “covered fund”), the Agencies did not propose any actual changes at that time. Accordingly, including such changes, for the first time, in the Final Rule arguably would not have been appropriate under the Administrative Procedures Act, because it would not have afforded interested parties the opportunity to review such proposals and, potentially, submit comments prior to the Agencies’ final action.

    [7] For a banking entity to use this exemption, the following criteria must be satisfied: (i) the banking entity is not organized, or directly or indirectly controlled, by a banking entity organized in a U.S. jurisdiction (including any U.S. territory or commonwealth); (ii) if the entity is a “foreign banking organization” under the Board’s Regulation K, it qualifies for the exemption; (iii) if the entity is not a “foreign banking organization” under the Board’s Regulation K, it must satisfy at least two of the following: (x) its total assets outside the United States exceed those held in the United States; (y) its total revenues from its non-U.S. business exceed those from its U.S. business; or (z) its total net income from its non-U.S. business exceed that from its U.S. business.

    [8] For an eligible non-U.S. banking entity to invest in a covered fund under this exemption, the fund must not sell its ownership interests in any offering that targets “U.S. persons.”

    [9] Other criteria that must be satisfied for the exemption to apply are the following: (i) the eligible banking entity (or office thereof) acting as principal (and that makes the decision to engage in the activity, if different) is not organized or located in the United States; (ii) no relevant personnel of the entity responsible for the decision to engage in the activity is located in the United States (excluding “back office” personnel); and (iii) the activity is not accounted for as principal, directly or indirectly, on a consolidated basis by a branch or affiliate organized or located in the United States.

    [10] See, e.g., FAQ 13, Frequently Asked Questions.

    [11] See supra note 6.

    [12] See supra note 7.

    [13] Because, for its purposes, the Volcker Rule both (i) expands the scope of entities to which Section 23A applies and (ii) replaces its requirements/limits with a prohibition.

    [14] These transactions, however, are subject to Section 23B of the Federal Reserve Act (i.e., the market terms requirement).

    [15] See, e.g., FAQ 18, Frequently Asked Questions.

    [16] Which for a United States banking entity is measured by the average gross sum of trading assets and liabilities (excluding those involving obligations of the U.S. or any U.S. agency), on a worldwide consolidated basis at the end of each of the previous consecutive four quarters. A non-U.S. banking entity need only include its combined U.S. operations (including all its affiliates or offices operating, located or organized in the U.S.) in its calculation.


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2019 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors
    More insights

  • Third Circuit Upholds Decision Blocking Trump Administration’s Birth Control Rules

    Third Circuit Upholds Decision Blocking Trump Administration’s Birth Control Rules

    ARTICLE / CLIENT ALERT / US POLICY

    Third Circuit Upholds Decision Blocking Trump Administration’s Birth Control Rules

    August 21, 2019

    Read time: 3 min

    Key takeaways
    Overview

    A Third Circuit appeals panel upheld the lower court ruling in Commonwealth of Pennsylvania v. President United States of America et al. No. 17-3752. This ruling grants a nationwide preliminary injunction against the religious and moral exemptions for employers to the ACA’s birth control mandate, so employers may want to take a cautious approach toward limiting contraceptive coverage.

    In depth

    A Third Circuit appeals panel upheld the lower court ruling in Commonwealth of Pennsylvania v. President United States of America et al. No. 17-3752, a ruling granting a nationwide preliminary injunction against the religious and moral exemptions for employers to the ACA’s birth control mandate. The decision was passed down in January by a Pennsylvania federal judge, and follows a sequence of similar appeals cases brought in the Ninth Circuit.

    In an opinion written by Circuit Judge Patty Shwartz, the panel found that the plaintiffs had proved particularized injury—rejecting the Trump Administration’s argument that the states lacked standing. The panel found there was evidence in the record showing the exemptions would result in increased spending of state-funded services either from women who have lost coverage or states bearing the costs of unintended pregnancies. This holding goes farther than the recent Ninth Circuit decision in The Little Sisters of the Poor Jeanne Jugan Residence v. California, et al. No. 18-1192, which limited injunction to the select states that brought the litigation because there was not a sufficient showing of economic injury.

    The appeals panel ruled it was necessary to halt the implementation of the rules until it has been decided whether or not the agencies responsible for the rules—the Departments of Health and Human Services, Treasury and Labor—followed the Administrative Procedure Act. The panel was not convinced by either argument presented: that there was good cause sufficient to avoid notice and comment or that the Religious Freedom Restoration Act required a religious exemption.

    Whether any appeal to the Supreme Court is in progress has yet to be determined. Accordingly, employers may want to take a cautious approach toward limiting contraceptive coverage.

    Authors
    More insights

  • For High-Cost, High-Value Patents, Fixed-Fee Procurement Could Be the Answer

    For High-Cost, High-Value Patents, Fixed-Fee Procurement Could Be the Answer

    ARTICLE

    For High-Cost, High-Value Patents, Fixed-Fee Procurement Could Be the Answer

    August 19, 2019

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Ahsan A. Shaikh

    Partner

    Silicon Valley, Chicago

    More insights

  • EU Token Regulation Paper

    EU Token Regulation Paper

    ARTICLE

    EU Token Regulation Paper

    August 2019

    Read time: 2 min

    Key takeaways
    Overview

    Dr. Sebastian Keding, Fabrice Piollet, Romain Desmonts, Emmanuelle Turek and Guillaume Béal contributed to the thinkBLOCKtank paper on The Regulation of Tokens in Europe, in particular, penning the French and German sections of the analysis.

    The aim of the EU Token Regulation Paper is to analyse the EU legal and regulatory framework applicable to token sales in Europe. The paper provides an overview of the relevant national legal and regulatory framework in a number of individual EU jurisdictions.

    In depth
    Authors

    Fabrice Piollet

    Partner

    Paris

    Romain Desmonts

    Partner

    Paris

    More insights

  • Healthcare Enforcement Quarterly Roundup | Q2 2019

    Healthcare Enforcement Quarterly Roundup | Q2 2019

    ARTICLE

    Healthcare Enforcement Quarterly Roundup | Q2 2019

    August 15, 2019

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Laura McLane

    Partner

    Boston

    Paul M. Thompson

    Partner

    Washington, DC

    More insights

  • Trustees of Revocable Trusts May Owe Duties to Contingent Beneficiaries

    Trustees of Revocable Trusts May Owe Duties to Contingent Beneficiaries

    ARTICLE / CLIENT ALERT

    Trustees of Revocable Trusts May Owe Duties to Contingent Beneficiaries

    August 15, 2019

    Read time: 9 min

    Key takeaways
    Overview

    Revocable trusts are a ubiquitous part of modern US estate planning because they avoid the delay, cost and publicity inherent in probate administration and, in the international context, because of the certainty they provide in establishing the trust as a grantor trust. During the settlor’s life, a revocable trust, in conjunction with a general power of attorney, allows for management of the settlor’s US estate without a conservatorship or guardianship. Following the settlor’s death, a revocable trust acts as a will substitute by disposing of the trust property without judicial involvement. Under US law, a settlor can achieve these advantages without sacrificing control over the trust property—or so many advisers thought.

    In depth

    Conversely, as a matter of English law (as well as the laws of the Crown Dependencies and British Overseas Territories), the trustee must owe enforceable obligations to the members of the beneficial class of a revocable trust from the moment the trust is settled. As a matter of English law, if the beneficiaries have no rights, then there is no trust. Armitage v. Nurse (1998). Except to the extent that a power has been expressly and appropriately reserved to the settlor, the trustee of even a revocable trust must not merely follow the instructions of the settlor. The trustee must possess an irreducible core of discretionary responsibilities—although the trustee should, in addition to the interests of the beneficial class, consider the settlor’s wishes in exercising its discretion. While the power to revoke is clearly a personal power of the settlor, and the settlor may exercise it purely for her own benefit, for so long as the trust exists the trustee’s obligations are to the beneficial class as a whole, and those obligations are fiduciary in nature and enforceable by the members of the beneficial class.

    Offshore there is one notable exception to the general rule that a trust requires that the “objects” of the trust (the beneficiaries) have standing to police the trustee. That exception is trusts created under the Cayman Special Trusts Alternative Regime (STAR trusts), which delegates standing to enforce the obligations owed to the beneficiaries to an “enforcer.” This statute was deeply controversial when introduced in 1997, but the STAR trusts have now become generally accepted as valid trusts. No other common law jurisdiction, however, has adopted similar legislation taking away the beneficiaries’ standing to police the trustee outside of the United States.

    It would be a vast overstatement to suggest that these two very different visions of a revocable trust are converging. However, in at least some US states, contingent beneficiaries of a revocable trust may in some limited circumstances have standing to invoke the supervisory jurisdiction of the courts over the trust. As a recent case in Michigan illustrates, some US states now grant rights to contingent beneficiaries of revocable trusts when the settlor ceases to have capacity. Because it is often unclear whether a settlor lacks capacity, a trustee of a US revocable trust should proceed with caution before following an instruction from the settlor that is inconsistent with any duties the trustee may owe to the contingent beneficiaries.

    In In re Rhea Brody Living Trust (2017), Robert and Rhea Brody, husband and wife, created separate revocable trusts to hold interests in two family businesses. Rhea subsequently became incapacitated and Robert began acting as successor trustee of Rhea’s revocable trust. As the trustee of his trust and Rhea’s trust, Robert sold all of the trusts’ interests in the family businesses to Robert and Rhea’s son, Jay. Rhea and Robert’s daughter, Cathy, subsequently filed a petition challenging the sale price and seeking Robert’s removal as successor trustee of Rhea’s trust.

    Robert and Jay both argued that Cathy, as a contingent beneficiary, did “not have standing to bring an action regarding the administration of a revocable trust.” In support of their argument, Robert and Jay alleged that Rhea’s trust remained revocable because (1) Rhea had not been declared “disabled” pursuant to the terms of the trust and (2) Robert, as Rhea’s agent under a durable power of attorney, could exercise Rhea’s power to revoke the trust. However, the Michigan Court of Appeals concluded that Cathy was an “interested person,” as defined under Michigan law, and thus had standing to commence an action concerning Rhea’s trust—whether or not the trust was revocable. In so holding, the court expressly rejected Robert and Jay’s request “to adopt the approach of other jurisdictions in holding that a contingent beneficiary lacks standing to challenge the administration of a revocable trust,” noting that their reliance on “the Uniform Trust Code and cases from other jurisdictions [was] misplaced” because Michigan had modified its version of the Uniform Trust Code.

    Following the decision of the Michigan Court of Appeals, Robert applied for leave to appeal to the Michigan Supreme Court. In lieu of granting leave, the Michigan Supreme Court remanded the case to the Michigan Court of Appeals “for reconsideration of its standing analysis.” On remand, the Michigan Court of Appeals again concluded that Cathy had standing to enforce the terms of Rhea’s trust, but on grounds more consistent with the peculiarities of Michigan law. The final decision in this case was reached on June 14, 2019. In lieu of granting a second application for leave to appeal, the Michigan Supreme Court vacated a portion of the Michigan Court of Appeal’s second opinion, but did not disturb the conclusion that Cathy had standing to enforce Rhea’s revocable trust.

    In its second opinion, the Michigan Court of Appeals determined that Cathy, as contingent beneficiary, had standing pursuant to Section 603 of the Uniform Trust Code (UTC) as enacted in Michigan. Section 603(b) of the UTC provides that:

    To the extent a trust is revocable [and the settlor has capacity to revoke the trust], rights of the beneficiaries are subject to the control of, and the duties of the trustee are owed exclusively to, the settlor.

    The phrase “and the settlor has capacity to revoke the trust” was not bracketed in the version of the UTC originally recommended for adoption in 2000. However, the comments to the UTC explain that this language was controversial, in part, because it may be difficult for trustees “to determine whether the settlor ha[d] become incapacitated and the settlor’s control of the beneficiary’s rights have ceased.” To address this concern, the Uniform Law Commission amended the UTC in 2004 to make the bracket language optional.

    Michigan’s version of the UTC does not include Section 603(b) or its optional bracketed language. However, Michigan’s version of the UTC includes an alternative provision that, as applied by the Michigan Court of Appeals in Brody, has the same effect as the bracketed language in Section 603(b).

    In Michigan, and in states that have enacted the UTC with the bracketed language from the Section 603(b), the trustee of a revocable trust owes duties exclusively to the settlor while the settlor has capacity. If the settlor loses capacity, then the “qualified beneficiaries,” which include presumptive remainder beneficiaries, acquire the right to receive information regarding the trust and standing to enforce the trustee’s duties.

    In UTC states that have not adopted the bracketed language from Section 603(b) of the model act, beneficiaries (other than the settlor or the settlor’s agent) generally do not have rights in or standing to enforce a revocable trust upon the settlor’s incapacity. See Manon v. Orr (2014). However, the precise approach varies from jurisdiction to jurisdiction. For example, in enacting the UTC, Florida declined to adopt the bracketed language from Section 603(b), but allows contingent remainder beneficiaries to sue the trustee of a revocable trust, after the settlor’s death, for a breach of duty owed to the settlor. Hilgendorf v. Estate of Coleman (2016) (citing Brundage v. Bank of America (2008)). The same rule exists in Texas, a state that has not adopted the UTC. Moon v. Lesikar (2007).

    Pending gubernatorial approval, Illinois will become the 34th state to enact the UTC, effective as of January 1, 2020. Consistent with its common law, Illinois’ version of the UTC includes the bracketed language from Section 603 of the model act. See In re Estate of Michalak (2010). Thus, in Illinois, contingent remainder beneficiaries of revocable trusts will continue to acquire standing to enforce the trust upon the settlor’s incapacity.

    The lessons here are as follows:

    • Trustees of revocable trusts should exercise caution before following an instruction given by a settlor or the settlor’s agent that may be contrary to the terms of the trust. If the settlor’s capacity is diminished or otherwise questionable, the trustee should review applicable law to determine the rights of the contingent remainder beneficiaries before following the instruction. A trust instrument may eliminate any rights the contingent remainder beneficiaries may have upon the settlor’s incapacity. Therefore, if the default provisions of applicable law grant rights to the contingent remainder beneficiaries upon the settlor’s incapacity, the trustee should determine whether the trust instrument eliminates such rights. Lastly, if such rights are not eliminated, the trustee should obtain a release from the contingent remainder beneficiaries or refuse to follow the instruction.
    • Conversely, a trustee of a foreign revocable trust owes enforceable obligations to the objects (beneficiaries) of the trust forthwith regardless of the settlor’s capacity. Trustees of even revocable trusts must have an irreducible core of discretionary obligations, and while they should consider the wishes of the settlor, they cannot merely follow her instructions. In the absence of these obligations enforceable by the beneficiaries (except Cayman STAR trusts) there is no trust, and there may be innumerable complications arising from whatever form of legal relationship the court will impose on the structure.
    Authors

    Joseph J. Viviano

    Partner

    Chicago

    More insights

  • INSIGHT: State Marijuana Laws and Drug Testing—A Decoding Ring for Employers

    INSIGHT: State Marijuana Laws and Drug Testing—A Decoding Ring for Employers

    ARTICLE

    INSIGHT: State Marijuana Laws and Drug Testing—A Decoding Ring for Employers

    August 14, 2019

    Read time: 1 min

    Key takeaways
    Overview

    Alice Kwak authored this bylined article discussing different state provisions and federal preemption issues related to marijuana and job drug testing.

    In depth
    Authors
    More insights